JP2004503232A - Ｃ／ＥＢＰβ発現のアンチセンスモジュレーション - Google Patents

Ｃ／ＥＢＰβ発現のアンチセンスモジュレーション Download PDF

Info

Publication number
JP2004503232A
JP2004503232A JP2002510501A JP2002510501A JP2004503232A JP 2004503232 A JP2004503232 A JP 2004503232A JP 2002510501 A JP2002510501 A JP 2002510501A JP 2002510501 A JP2002510501 A JP 2002510501A JP 2004503232 A JP2004503232 A JP 2004503232A
Authority
JP
Japan
Prior art keywords
acid
ebpβ
antisense
oligonucleotide
antisense compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002510501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004503232A5 (enExample
Inventor
モニア，ブレット・ピー
バトラー，マデリン・エム
ワイアット，ジャクリーン・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of JP2004503232A publication Critical patent/JP2004503232A/ja
Publication of JP2004503232A5 publication Critical patent/JP2004503232A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002510501A 2000-06-14 2001-06-11 Ｃ／ＥＢＰβ発現のアンチセンスモジュレーション Withdrawn JP2004503232A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/593,711 US6271030B1 (en) 2000-06-14 2000-06-14 Antisense inhibition of C/EBP beta expression
PCT/US2001/018763 WO2001096360A1 (en) 2000-06-14 2001-06-11 Antisense modulation of c/ebp beta expression

Publications (2)

Publication Number Publication Date
JP2004503232A true JP2004503232A (ja) 2004-02-05
JP2004503232A5 JP2004503232A5 (enExample) 2005-02-03

Family

ID=24375831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002510501A Withdrawn JP2004503232A (ja) 2000-06-14 2001-06-11 Ｃ／ＥＢＰβ発現のアンチセンスモジュレーション

Country Status (5)

Country Link
US (2) US6271030B1 (enExample)
EP (1) EP1294737A1 (enExample)
JP (1) JP2004503232A (enExample)
AU (1) AU2001268307A1 (enExample)
WO (1) WO2001096360A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544288A (ja) * 2019-08-14 2022-10-17 コディアック バイオサイエンシーズ， インコーポレイテッド ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121973A1 (en) * 2002-02-05 2004-06-24 Monia Brett P Antisense modulation of protein phosphatase 2 Catalytic subunit alpha expression
US20030166592A1 (en) * 1999-07-19 2003-09-04 Monia Brett P. Antisense modulation of liver glycogen phosphorylase expression
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
JP4534092B2 (ja) * 2000-09-08 2010-09-01 第一三共株式会社 心不全治療剤
US20030083304A1 (en) * 2001-10-09 2003-05-01 Smart Robert C. CCAAT/enhancer binding protein-beta (C/EBPbeta) is a molecular target for cancer treatment
AU2003203527A1 (en) * 2002-04-12 2003-10-30 Sumitomo Electric Industries, Ltd. Control of the ratio of lap to lip
US20030232773A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of DRAK1 expression
US20040077084A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
AU2004220459B2 (en) * 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2005286663A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
IL177989A0 (en) * 2006-09-10 2006-12-31 Yeda Res & Dev Use of transcription factor inhibitor in the manufacture of a medicament
GB202019692D0 (en) * 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2686565B2 (ja) 1989-12-25 1997-12-08 忠三 岸本 Ｃ／ｅｂｐ２遺伝子及びリコンビナントｃ／ｅｂｐ２
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544288A (ja) * 2019-08-14 2022-10-17 コディアック バイオサイエンシーズ， インコーポレイテッド ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物

Also Published As

Publication number Publication date
WO2001096360A1 (en) 2001-12-20
EP1294737A1 (en) 2003-03-26
AU2001268307A1 (en) 2001-12-24
US20060030045A1 (en) 2006-02-09
US6271030B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
JP4054192B2 (ja) Ｐｔｐ１ｂ発現のアンチセンス阻害
JP4397585B2 (ja) クラスタリン発現のアンチセンスモジュレーション
AU770526B2 (en) Antisense modulation of PI3K P85 expression
JP2003505351A (ja) Ｍａｐキナーゼキナーゼ６発現のアンチセンスモジュレーション
JP2003520241A (ja) Ｍｅｋｋ２発現のアンチセンスモジュレーション
JP2004509619A (ja) Ｆｌｉｐ−ｃ発現のアンチセンスモジュレーション
JP2003520586A (ja) Ｓｍａｄ７発現のアンチセンスモジュレーション
JP2003505027A (ja) Ｐｉ３キナーゼｐ１１０デルタ発現のアンチセンスモジュレーション
JP2003520042A (ja) 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
JP2003505062A (ja) Ｐｔｅｎ発現のアンチセンスモジュレーション
AU768799B2 (en) Antisense modulation of integrin-linked kinase expression
JP2003505063A (ja) Ｍｅｋｋ５発現のアンチセンスモジュレーション
JP2003520585A (ja) ペルオキシソーム増殖因子−活性化受容体ガンマ発現のアンチセンスモジュレーション発現のアンチセンスモジュレーション
JP2003505092A (ja) Ｓｈｐ−２発現のアンチセンスモジュレーション
JP2003520051A (ja) Ｐｅｐｃｋ−サイトゾル発現のアンチセンスモジュレーション
JP2003508089A (ja) ＰＩ３キナーゼｐ１１０ベータ発現のアンチセンスモジュレーション
JP2004503232A (ja) Ｃ／ＥＢＰβ発現のアンチセンスモジュレーション
JP2003505026A (ja) 肝臓グリコーゲンホスホリラーゼ発現のアンチセンスモジュレーション
JP2003531630A (ja) Ｄｎａ結合阻害剤−１発現のアンチセンスモジュレーション
JP2003525058A (ja) Ｅ２ｆ転写因子１発現のアンチセンスモジュレーション
AU753245B2 (en) Antisense modulation of Cellular Inhibitor of Apoptosis-1 expression
JP2003518928A (ja) Ａｋｔ−３発現のアンチセンスモジュレーション
JP2003527085A (ja) Ｐｅｐｃｋ−ミトコンドリア発現のアンチセンスモジュレーション
JP2005525829A (ja) 糖質コルチコイド受容体発現のアンチセンス調節
JP2003512079A (ja) タンパク質キナーゼｃ−シータ発現のアンチセンスモジュレーション

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20050204